Advertisement
BMY vs LLY
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- Different growth profiles: LLY is delivering high double-digit revenue growth driven by its metabolic franchise, while BMY is managing a transition from declining legacy drugs to a newer growth portfolio.
- Valuation gap: LLY trades at a premium multiple reflecting faster growth, whereas BMY trades at a lower earnings multiple and offers a higher dividend yield.
- Momentum divergence: LLY has reached record highs on obesity-drug demand, while BMY has posted solid but more modest gains and faces periodic pipeline-safety headlines.
- Risk profiles differ: LLY carries concentration and competition risk in weight-loss drugs; BMY faces patent expirations and generic erosion across its legacy portfolio.
- Analyst posture: Consensus leans "Buy" on LLY and "Hold" on BMY, reflecting differing growth visibility and catalysts.
- For deeper coverage, explore BMY Major News and BMY Today's Price Move, as well as LLY Major News and LLY Today's Price Move.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Introduction
Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) are two of the largest pharmaceutical companies in the United States, yet they sit at very different points in their business cycles. This stock comparison is relevant for investors weighing a value-oriented turnaround story against a high-growth momentum leader, and for traders tracking relative performance and market positioning across large-cap healthcare. By examining recent stock behavior, growth drivers, and risk factors side by side, readers can better understand how each company is navigating the current market environment and which characteristics may align with their own objectives.
BMY Overview and Recent Performance
Bristol-Myers Squibb is a diversified biopharmaceutical company focused on oncology, hematology, immunology, and cardiovascular medicine. In recent weeks, the stock has traded in the low $60s, supported by better-than-expected quarterly results in which adjusted earnings and revenue exceeded analyst estimates and full-year guidance was reaffirmed toward the higher end of its range. The company's growth portfolio, including Camzyos, Breyanzi, Reblozyl, and the subcutaneous formulation Opdivo Qvantig, has expanded at a double-digit pace and now represents more than half of total revenue. This strength is helping offset continued generic erosion in legacy products such as Revlimid, Pomalyst, and Sprycel, while the blood thinner Eliquis, co-marketed with Pfizer, remains a major revenue contributor. Sentiment has been tempered by a patient death in an early-stage CAR T cell therapy trial for multiple sclerosis, a reminder of the binary risks embedded in the pipeline. BMY also offers an attractive dividend yield near 4% backed by a long history of payout increases.
LLY Overview and Recent Performance
Eli Lilly is a global pharmaceutical leader whose recent performance has been driven overwhelmingly by its metabolic franchise, anchored by the diabetes and obesity treatments Mounjaro and Zepbound. In recent weeks, LLY shares have climbed to all-time highs, with the stock posting strong double-digit year-to-date gains and a one-year return of roughly 60%. Recent quarterly results showed revenue rising nearly 50% year over year, powered by surging volume despite lower realized prices. The launch of Foundayo, an oral GLP-1 (glucagon-like peptide-1) treatment, and the expansion of Medicare coverage for obesity medicines have broadened the company's addressable market and supported investor enthusiasm. Lilly has also invested heavily in new manufacturing capacity and completed multiple acquisitions to diversify its pipeline. Consensus sentiment remains bullish, though the stock's premium valuation leaves less margin for error around execution and competitive pricing pressures from rivals such as Novo Nordisk.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of automated trading strategies from a much larger library. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a small subset earns placement in this featured section—typically around two dozen robots chosen for their suitability to current market conditions. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of tickers, with published metrics including win rates, profit factors, and trade durations that vary widely across the lineup. Because no single approach fits every market, this curated view helps traders identify strategies that are currently resonating with prevailing conditions. For those interested in how AI-driven systems are positioning themselves today, exploring Trending AI Robots offers a practical starting point.
Head-to-Head Comparison
The core contrast between these two companies is momentum versus transition. LLY is a growth engine, expanding revenue at a rapid clip on the back of a dominant metabolic franchise, but it also carries concentration risk—much of its value rests on a small number of products and on defending market share against intensifying competition. Its premium valuation and elevated investor expectations mean even strong results can be met with volatility. BMY, by contrast, is a steadier, income-oriented story. Its lower multiple and substantial dividend reflect a more mature business navigating patent cliffs, yet its growth portfolio and pipeline offer a pathway to offset legacy declines. From a sector-exposure standpoint, both are large-cap healthcare names that can benefit from defensive rotation, but LLY's faster growth and record-setting price action give it greater upside sensitivity, while BMY's yield and valuation provide a more conservative relative positioning. Market sentiment currently favors LLY, but BMY offers a different risk-reward trade-off centered on stability and income.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and catalyst visibility, Tickeron's AI would likely lean toward LLY in the current environment. The stock's sustained uptrend, record highs, and robust demand-driven revenue growth suggest stronger trend consistency and positive market positioning. However, this is a probabilistic assessment rather than a definitive one—LLY's premium valuation and competitive pressures introduce downside sensitivity, while BMY's lower volatility and reliable dividend may appeal more to stability-focused strategies. The AI's preference is therefore conditional on prevailing momentum rather than a judgment about long-term value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and LLY is a Hold.
BMY's Indicator enters downward trend
The Aroon Indicator for BMY entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 103 of the 186 cases the stock moved lower. This puts the odds of a downward move at 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 68 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 13 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 49 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 25 of 49 cases over the following month. The odds of a continued upward trend are 51%.
BMY moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly worse than average.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.360). P/E Ratio (13.627) is within average values for comparable stocks, (21.695). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
LLY's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for LLY moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 instances where the indicator moved out of the overbought zone. In 23 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a move down at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where LLY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 55 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 216 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.360). P/E Ratio (45.360) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
BMY | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 4 | |
SMR RATING 1..100 | 22 | 14 | |
PRICE GROWTH RATING 1..100 | 42 | 4 | |
P/E GROWTH RATING 1..100 | 60 | 45 | |
SEASONALITY SCORE 1..100 | 65 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY's Valuation (86) in the Pharmaceuticals Major industry is in the same range as BMY (96). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
LLY's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66). This means that LLY’s stock grew somewhat faster than BMY’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
LLY's Price Growth Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (42). This means that LLY’s stock grew somewhat faster than BMY’s over the last 12 months.
LLY's P/E Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as BMY (60). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
| BMY | LLY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 43% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 54% | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 58% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 69% |
| Advances ODDS (%) | 6 days ago 56% | 9 days ago 70% |
| Declines ODDS (%) | 1 day ago 55% | 1 day ago 54% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 53% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 73% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while LLY’s FA Score has 3 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 6 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.54% price change this week, while LLY (@Pharmaceuticals: Major) price change was -4.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
Reported Earning Dates
BMY is expected to report earnings on Feb 04, 2027.
LLY is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.